mGem: Progress on the development of conjugate vaccines for Cryptococcus neoformans infections

Cryptococcus neoformans is an important fungal pathogen that causes cryptococcosis, a life-threatening disease predominantly affecting immunocompromised individuals. Current estimates suggest that cryptococcosis is responsible for over 150,000 deaths annually, highlighting the need for the development of effective preventive measures. Early research utilizing polysaccharide filtrates (CneF) laid the groundwork for polysaccharide-containing vaccines, demonstrating partial protection in murine infection models. Further vaccine constructs made with purified extracellular polysaccharides (EPS) conjugated to protein carriers elicited strong antibody responses and enhanced survival. Recently, more attention was given to the purified capsule components glucuronoxylomannan (GXM) and glucuronoxylomannogalactan (GXMGal), with studies indicating that GXM conjugates can elicit protective effects. The development of semisynthetic polysaccharide-based vaccines offers a new approach to addressing lot-to-lot variability, enhancing consistency. In conclusion, strategies that advance from early crude formulations to more sophisticated conjugate and synthetic vaccines hold great promise for developing an effective vaccine to prevent and treat cryptococcal diseases.